A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of different combinations of cancer drugs compared to either nivolumab and ipilimumab or one another in participants with metastatic kidney cancer.
*Must be 18 years of age or older.
*Subject have confirmed diagnosis of kidney cancer.
*Patients cannot have had any other treatment for their kidney cancer
*Have tumor samples available for testing
*Subject's medical history will be reviewed in detail for study eligibility.
18 - 120
Healthy Volunteers Needed
Duration of Participation
Patients will stay in the study as long as they receive clinical benefit.
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com